Repaglinide Overview and Content Structure

Repaglinide is a non-sulfonylurea insulin secretagogue used to treat type 2 diabetes. It helps control blood sugar by stimulating the release of insulin from the pancreas. This article will start from five aspects: its mechanism of action, applicable groups, medication precautions, common products on the market and clinical data, focusing onEfficacy, safety and instructions for useProvide explanations, avoid exaggerated propaganda, and ensure the information is objective and reliable.

Mechanism of action and core efficacy

Repaglinide passedRapid activation of potassium channels on pancreatic beta cells, promote insulin secretion, especially suitable for postprandial blood sugar control. It is characterized by fast onset of action (within 15 minutes), short action time (about 4 hours), and needs to be taken before meals. Compared with sulfonylureas, the risk of hypoglycemia is relatively low, but dosage adjustment is required in patients with renal insufficiency. Clinical studies have shown that repaglinide can reduce glycated hemoglobin (HbA1c) by approximately 1.5%-2%.

Applicable groups and medication precautions

This medicine is mainly used forAdults with type 2 diabetes, especially suitable for those with poor diet and exercise control. Contraindications include patients with type 1 diabetes, ketoacidosis and pregnant women. It is necessary to strictly follow the doctor's instructions when taking the medication, and avoid using it in combination with drugs such as gemfibrozil (which may increase the risk of hypoglycemia). Common side effects are mild dizziness or gastrointestinal reactions, most of which resolve spontaneously.

Market products and manufacturers

Summary and clinical significance

As an auxiliary drug for diabetes management, repaglinide balances efficacy and safety, but it requires individualized medication. Patients should monitor blood sugar regularly and cooperate with lifestyle intervention. At present, major domestic manufacturers include Hansoh Pharmaceuticals and Novo Nordisk. The specific medication plan needs to be evaluated by a doctor.

Citing sources

1. "China Type 2 Diabetes Prevention and Treatment Guidelines (2023 Edition)"
2. Novo Nordisk official website: Repaglinide (Novoron) product instructions
3. Hansoh Pharmaceuticals: Clinical data of Fulaidi (repaglinide tablets)